China Tian Yuan Healthcare Group Limited (0557) AI Stock Analysis

• Market Cap: HK$327.16M
• Dividend Yield: N/A
• Average Volume (3M): 2.67K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.78
• Revenue Growth: -43.78%
• EPS Growth: -118.13%
• Country: HK
• Employees: 34
• Sector: Healthcare
• Sector Strength: 45
• Industry: Travel Lodging
• EPS (TTM): >-0.01
• Shares Outstanding: 398,979,520
• 10 Day Avg. Volume: 8,000
• 30 Day Avg. Volume: 2,666
• PEG Ratio: -0.05
• Price to Book (P/B): 1.07
• Price to Sales (P/S): 7.73
• P/FCF Ratio: 19.44
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 42 Neutral
• Price Target: HK$1.00 ▲(13.64% Upside)

The overall stock score is primarily influenced by significant financial challenges and bearish technical indicators. The company's negative P/E ratio and lack of dividend yield further contribute to a low valuation score, indicating potential risks for investors.

China Tian Yuan Healthcare Group Limited Business Overview & Revenue Model

Company Description

China Tian Yuan Healthcare Group Limited (0557) is a healthcare company based in China, engaged primarily in the research, development, manufacturing, and distribution of pharmaceutical products and healthcare services. The company operates in various sectors including traditional Chinese medicine, modern pharmaceuticals, and health management services. Its core offerings encompass a wide range of medications, health supplements, and integrated healthcare solutions aimed at improving patient outcomes and promoting overall health.

How the Company Makes Money

China Tian Yuan Healthcare Group Limited generates revenue through multiple channels, primarily focusing on the sale of pharmaceutical products and healthcare services. The company earns a significant portion of its income by manufacturing and distributing prescription drugs and over-the-counter medications. Additionally, the company offers health management services, which include wellness programs and consultations that contribute to its revenue. Strategic partnerships with healthcare institutions and distributors further bolster its market reach and sales volume. The growing demand for healthcare products in China, driven by an aging population and increased health awareness, serves as a vital factor in enhancing the company's earnings.

China Tian Yuan Healthcare Group Limited Financial Statement Overview

Summary

China Tian Yuan Healthcare Group Limited is facing significant financial challenges, with declining revenues and persistent losses impacting profitability. Although the balance sheet shows a strong equity position, the cash flow improvements are overshadowed by volatility and past inefficiencies. The company needs strategic adjustments to improve profitability and leverage cash flow stability.

Income Statement

The company has seen a consistent decline in revenue over the years, with significant negative figures in EBIT and net income indicating ongoing profitability issues. Gross profit margin is high but overshadowed by persistent losses, suggesting challenges in controlling operating expenses.

Balance Sheet

The company's debt-to-equity ratio is relatively low, indicating conservative leverage. However, the significant decline in stockholders' equity due to consistent losses raises concerns. The equity ratio remains strong, showing a robust capital structure despite financial challenges.

Cash Flow

Positive operating cash flow in recent years is a positive sign, suggesting some operational efficiency. However, free cash flow has been volatile, and prior negative figures highlight potential issues in managing cash effectively. Improvement in free cash flow is notable but needs sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	26.41M	26.84M	45.23M	54.22M	94.59M	56.34M
Gross Profit	21.80M	14.91M	24.98M	34.83M	71.31M	37.57M
EBITDA	-30.06M	-27.22M	-15.79M	-27.10M	-2.89M	-102.17M
Net Income	-46.01M	-34.24M	-15.48M	-29.04M	-16.85M	-65.10M
Balance Sheet
Total Assets	263.11M	260.93M	302.95M	333.55M	376.40M	381.30M
Cash, Cash Equivalents and Short-Term Investments	28.29M	27.05M	26.73M	31.60M	77.89M	71.08M
Total Debt	40.80M	40.93M	45.91M	51.13M	59.66M	55.06M
Total Liabilities	90.61M	84.98M	87.77M	91.52M	92.35M	83.91M
Stockholders Equity	193.98M	194.68M	230.26M	224.30M	256.25M	267.53M
Cash Flow
Free Cash Flow	7.17M	10.67M	4.51M	-31.71M	14.86M	49.20M
Operating Cash Flow	7.18M	10.69M	5.10M	-30.36M	16.32M	49.54M
Investing Cash Flow	-4.50K	-3.00K	364.00K	-1.23M	-1.42M	-11.22M
Financing Cash Flow	-10.88M	-10.85M	-8.77M	-12.49M	-7.22M	-2.54M

China Tian Yuan Healthcare Group Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.88
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Positive
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0557, the sentiment is Negative. The current price of 0.88 is above the 20-day moving average (MA) of 0.86, above the 50-day MA of 0.85, and above the 200-day MA of 0.73, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 18.09 is Positive, neither overbought nor oversold. The STOCH value of 81.03 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0557.

China Tian Yuan Healthcare Group Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0199	―	HK$480.82M	―	-31.95%	―	180.75%	-26.19%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
0219	―	HK$281.39M	―	-4.72%	―	3.58%	-91.61%
0617	―	HK$339.95M	-0.20	-19.01%	―	-2.75%	-17.31%
0557	―	HK$327.16M	―	-15.15%	―	-43.78%	-118.13%
0078	―	€548.26M	-0.31	-29.62%	―	-0.60%	34.74%
0355	―	HK$235.04M	―	-18.68%	―	-3.51%	-15.27%

China Tian Yuan Healthcare Group Limited Corporate Events

China Tian Yuan Healthcare Group Reports Interim 2025 Financial Results

China Tian Yuan Healthcare Group Limited reported its unaudited consolidated results for the six months ending June 30, 2025, showing a decrease in revenue from HK$14,861,000 in 2024 to HK$8,436,000 in 2025. Despite a reduction in the cost of sales and a reversal of expected credit loss, the company experienced a loss before taxation of HK$5,538,000, which is an improvement from the previous year’s loss of HK$8,983,000. This financial performance indicates challenges in maintaining profitability, impacting stakeholders’ confidence.

The most recent analyst rating on (HK:0557) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on China Tian Yuan Healthcare Group Limited stock, see the HK:0557 Stock Forecast page.

China Tian Yuan Healthcare Issues Profit Warning Amid Revenue Decline

China Tian Yuan Healthcare Group Limited has issued a profit warning, indicating a significant decrease in revenue for the first half of 2025. The company’s revenue is expected to fall by 44% compared to the same period in 2024, primarily due to the temporary suspension and renovation of its Shanghai-based plastic surgery hospital. Despite a reduction in operating costs, the group anticipates a net loss of approximately HKD8.4 million for the period. The interim results are yet to be finalized, and shareholders are advised to exercise caution.

China Tian Yuan Healthcare Group Schedules Board Meeting to Review Interim Results

China Tian Yuan Healthcare Group Limited has announced an upcoming board meeting scheduled for August 29, 2025. The meeting will focus on reviewing and approving the company’s unaudited interim results for the first half of 2025 and discussing the potential payment of an interim dividend. This announcement may impact stakeholders by providing insights into the company’s financial health and potential shareholder returns.